In the ARROW trial, researchers found that different RET fusion partners affected the durability of patients' responses, a finding that could be useful for guiding treatment.
In cardiovascular medicine, claims of ‘mortality reduction’ are widely used to summarise the benefits of contemporary ...
Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study. This is an ASCO ...
Our study is motivated by evaluating the role of hematopoietic cell transplantation (HCT) after chimeric antigen receptor T-cell (CAR-T) therapy for ALL, a debated topic. Because patients may receive ...
Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge ...
Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk of mortality from idiopathic pulmonary fibrosis (IPF). A team of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results